DJS Antibodies CSO, Joe Illingworth is delighted to be speaking next week at BioTrinity 2022. As part of the session focusing on Inflammatory Disease Joe will be describing the nomination of our clinical development candidate mAb DJS-002. This is the first monoclonal antibody antagonist of the lipid receptor LPAR1, a clinically validated target with important roles in a number of fatal fibrotic and inflammatory diseases. DJS-002 has the potential to extend and improve many patient’s lives, and showcases the power of our discovery platform to deliver unique, first-in-class medicines.
The event will be taking place in person at etc Venues, 155 Bishopsgate, Liverpool Street, London EC2M 3YD.
For more information and to register for the event see the link below
www.biotrinity.com
